SCHAUMBURG, Ill., Sept. 16 Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company with a focus on injectable products, today announced that Ronald E. Pauli, Sagent's chief financial officer will present at the UBS Global Life Sciences Conference at 4:30 p.m. on Monday, September 21, 2009.
The conference, which is taking place on September 21-23, 2009 at the Grand Hyatt Hotel in New York, NY will feature presentations by more than 250 public and private biotechnology, medical device, pharmaceutical and specialty pharmaceutical companies. The conference is open to clients of UBS Investment Bank by invitation only.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.
To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.
SOURCE Sagent Pharmaceuticals, Inc.